Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;18(1):107-116.
doi: 10.1016/S1474-4422(18)30368-5. Epub 2018 Nov 21.

Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis

Sara E Mole  1 , Glenn Anderson  2 , Heather A Band  3 , Samuel F Berkovic  4 , Jonathan D Cooper  5 , Sophia-Martha Kleine Holthaus  6 , Tristan R McKay  7 , Diego L Medina  8 , Ahad A Rahim  9 , Angela Schulz  10 , Alexander J Smith  6
Affiliations
Review

Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis

Sara E Mole et al. Lancet Neurol. 2019 Jan.

Abstract

Treatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders that affect children. Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen for many genes. The identification of disease-causing mutations in 13 genes provides a basis for understanding the molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies. These targeted therapies include enzyme replacement therapies, gene therapies targeting the brain and the eye, cell therapies, and pharmacological drugs that could modulate defective molecular pathways. Such therapeutic developments have the potential to enable earlier diagnosis and better targeted therapeutic management. The first approved treatment is an intracerebroventricularly administered enzyme for neuronal ceroid lipofuscinosis type 2 disease that delays symptom progression. Efforts are underway to make similar progress for other forms of the disorder.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms